Monthly Archives: April 2023

SECRO, THE DOCUSIGN FOR BILLS OF LADING (eBLs), RAISES AN OVERSUBSCRIBED SEED ROUND LED BY AUGMENT VENTURES AND TMV WITH A MISSION TO TRANSFORM GLOBAL TRADE

NEW YORK, April 27, 2023 — Secro, a US-based technology company and digital bill-of-lading platform known as Secro e-Bill today announced an oversubscribed $3.6M in seed funding led by Augment Ventures alongside TMV, with participation by Kluz Ventures and Grit and Gumption Ventures. Secro is co-founded and led by Michele Sancricca, former Head of Supply Chain Technology at Amazon Web Services and Director of Business Transformation at MSC—the world’s largest shipping company. Secro’s platform enables users to perform all the functions of a paper bill of lading with increased speed, seamless user interaction, lower cost and unmatched security, without the need for the cumbersome private agreements used by other electronic bill of lading (eBL) providers.

For centuries, trade documentation has been a time-consuming and resource-intensive process, requiring countless documents and significant contribution from key stakeholders. A single shipment can require up to 50 sheets of paper that get exchanged with up to 30 different parties. The bill of lading, (a detailed list of a shipment issued by the carrier as a form of receipt to the buyer), is one of the industry’s most important trade documents. McKinsey analysis estimates that it accounts for roughly 10-30% of total trade documentation costs. And yet, it remains largely reliant on the physical transfer of paper records.

Secro—built on the NEM Symbol private blockchain—solves this massive challenge by enabling users to easily export proof of original documents, attach supporting files to the e-bill of lading and convert the latter into paper form, seamlessly fulfilling the compliance prerequisites and local customs requirements. Secro also allows users to share their electronic bill of lading (eBL) with partners—allowing multiple teams to work together on eBL drafts—as well as invite internal and external employees to collaborate.

Said Augment Ventures Founder and Managing Partner, Sonali Vijayavargiya: “There has never been a digital bill-of-lading solution that functions like Secro. It’s a game-changer in an industry that is destined to witness seismic transformation in the next few years. The timing is right for Secro to streamline and massively impact the future of global trade.”

Remarks Marina Hadjipateras, General Partner at TMV: “The maritime and logistics industries have made great progress toward digitization and operations across the past several years; Secro is doubling down on that progress—and accelerating it—by addressing a core element of the global trade process, solving its challenges, and building sustainability practices into the industry.

While current electronic bill-of-lading (eBL) providers follow complex rulebooks that serve as a mutual agreement to treat the eBL as equivalent to its paper counterpart, Secro’s proprietary software leverages Singapore’s Electronic Transactions Act (ETA), which deems eBLs operationally equivalent to paper. Secro’s technology creates a digitally native token that represents the bill of lading on a digital ledger—in alignment with the requirements of Singapore law. Given the company’s innovative legal construct, Secro’s eBL has force of law and legal acceptability across the world under a simple user form—without the need for a private rulebook agreement.

In fact, Secro recently completed the world’s first-ever paperless end-to-end transfer without a private agreement, partnering with fertilizer trading company Nitron Group of Connecticut in a deal involving six counterparties across three continents to move a shipment of liquid fertilizer from North America to Chile.

Secro will use this fresh round of capital to officially scale its platform, develop new features, and expand its network of business partners.

Says Sancricca: “We are ready to create relationships with new businesses, evolve
our offering, and bring innovation and change to an industry that is long overdue.” 

SOURCE Secro Inc


Genstar Capital Closes Fund XI With $12.6 Billion of Committed Capital

SAN FRANCISCO, April 27, 2023 — Genstar Capital, a leading private equity firm focused on investments in targeted segments of the financial services, healthcare, industrials, and software industries, today announced the first and final closing of Genstar Capital Partners XI (“Fund XI”) with approximately $12.6 billion in total commitments. In addition, Genstar raised committed overage capacity from select limited partners which will co-invest in Fund XI’s larger transactions. The General Partner and affiliated entities are collectively the largest investor in Fund XI and will continue to be led by Managing Partners Ryan Clark, Jean-Pierre Conte, Rob Rutledge, Tony Salewski, and Eli Weiss.

Fund XI reached its hard cap with strong support from its existing investor base and an expanded group of limited partners, including leading global endowments and foundations, public and corporate pension plans, sovereign wealth funds, financial institutions, and family offices. Genstar’s previous fund, Genstar Capital Partners X, closed in April 2021 with approximately $10.2 billion of total committed capital.

Genstar will continue to make control investments in middle market companies primarily headquartered in North America. The firm is 100% employee owned and operates from a single office in San Francisco. The investment team is complemented by a group of 31 Strategic Advisors, who are current and former business leaders, working side by side with the Genstar investment team.

Evercore Partners served as Placement Agent for the fund and Weil, Gotshal & Manges LLP provided legal advice.

About Genstar
Genstar Capital (www.gencap.com) is a leading private equity firm that has been actively investing in high-quality companies for over 30 years. Based in San Francisco, Genstar works in partnership with its management teams and its network of strategic advisors to transform its portfolio companies into industry-leading businesses. Together with Genstar XI and all active funds, Genstar currently has approximately $49 billion of assets under management and targets investments focused on targeted segments of the financial services, healthcare, industrials, and software industries.

Contact: Chris Tofalli
Chris Tofalli Public Relations, LLC
914-834-4334

SOURCE Genstar Capital


Biomica Announces Closing of $20 Million Financing Round led by Shanghai Healthcare Capital

About Biomica Ltd.:

Biomica is a clinical stage biopharmaceutical company developing innovative microbiome-based therapeutics utilizing MicroBoost AI tech-engine, licensed from Evogene. Biomica aims to identify and characterize disease-related microbiome entities and to develop novel therapeutics based on these understandings. The company is focused on the development of therapies for antibiotic resistant bacteria, immuno-oncology, and microbiome-related gastrointestinal (GI) disorders. Biomica is a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN).

For more information, please visit www.biomicamed.com.

About Evogene Ltd.:

Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN) is a computational biology company aiming to revolutionize the development of life-science based products by utilizing cutting edge technologies to increase the probability of success while reducing development time and cost. Evogene established three unique tech-engines – MicroBoost AI, ChemPass AI and GeneRator AI – leveraging Big Data and Artificial Intelligence and incorporating deep multidisciplinary understanding in life sciences. Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI).

Evogene uses its tech-engines to develop products through subsidiaries and strategic partnerships. Evogene’s subsidiaries currently utilize the tech-engines to develop human microbiome-based therapeutics by Biomica, ag-biologicals by Lavie Bio, ag-chemicals by AgPlenus, medical cannabis products by Canonic and castor varieties, for the biofuel and other industries, by Casterra. 

For more information, please visit www.evogene.com

Forward Looking Statements

This press release contains “forward-looking statements” relating to future events. These statements may be identified by words such as “may”, “could”, “expects”, “hopes” “intends”, “anticipates”, “plans”, “believes”, “scheduled”, “estimates”, “demonstrates” or words of similar meaning. For example, Evogene and its subsidiaries are using forward-looking statement in this press release when it discusses the BMC128 phase 1 immuno-oncology study and the advancement to phase 2 clinical trial; scale up and completion of GMP production of BMC333 in preparation for a phase 1 clinical trial for the treatment of inflammatory bowel disease (IBD) and advancement of additional programs. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, those risk factors contained in Evogene’s reports filed with the applicable securities authority. In addition, Evogene and its subsidiaries rely, and expect to continue to rely, on third parties to conduct certain activities, such as their field-trials and pre-clinical studies, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, Evogene and its subsidiaries may experience significant delays in the conduct of their activities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

Logo – https://mma.prnewswire.com/media/1974949/Biomica.jpg
Logo – https://mma.prnewswire.com/media/1947468/Evogene.jpg

SOURCE Biomica Ltd.


Antiva Biosciences Closes $53 Million Series E Equity Financing Led by MPM-BioImpact Capital and Names Kristine Ball President and CEO

Proceeds to Support Key Efficacy Studies for ABI-2280 including Phase 2 Trial in High-Grade Cervical Intraepithelial Neoplasia (CIN 2,3) and Exploratory Study as Treatment for High-Risk HPV Infections

SOUTH SAN FRANCISCO, April 27, 2023 — Antiva Biosciences, a biopharmaceutical company developing novel, topical therapeutics for the treatment of pre-cancerous lesions caused by human papilloma virus (HPV) infection, today announced the closing of a $53 million Series E equity financing. The financing was supported by a syndicate of premier life science investors led by MPM-BioImpact Capital, and joined by the company’s existing investors including Canaan Partners, Sofinnova Investments, Adjuvant Capital, GV and Lumira Ventures, among others. In conjunction with the financing, president and chief executive officer Gail Maderis is transitioning to chairman of the company’s board of directors and is being succeeded as CEO by Kristine Ball. Additionally, Ms. Ball, along with Florencia Segal, M.D., and Brian Goodman, Ph.D., both of MPM-BioImpact Capital, will join the Antiva board.

Proceeds from the financing, which will fund the company into late 2025, will support the advancement of the company’s lead development candidate, ABI-2280, into key efficacy studies following completion of its ongoing Phase 1 trials. Planned studies include a Phase 2 clinical trial in high-grade cervical intraepithelial neoplasia (CIN 2,3) and an exploratory study as a potential treatment for high-risk HPV infection, specifically in subtypes that can lead to cancer. ABI-2280 has potent antiviral activity across all serotypes of HPV and works by both directly blocking HPV replication and inducing apoptosis in HPV-infected lesions, while sparing normal cells. Antiva has leveraged its development expertise to formulate a vaginal tablet of ABI-2280 that will enable self-administration at diagnosis and facilitate worldwide distribution, increasing impact potential for patients.

The treatment of high-risk HPV infections with ABI-2280 holds the potential to address a significant global health challenge. HPV infections account for nearly all cases of cervical cancer around the world and an accessible and effective treatment holds the promise to dramatically reduce these cancers. Currently, there are no treatments available to resolve HPV infections and prevent their development into cancer. This remains a crucial unmet medical need with more than 5.5 million women in United States alone affected by high-risk HPV infections each year despite ready access to vaccines.

“We believe that Antiva has the opportunity to make a transformative impact on global health across several large, unmet therapeutic indications with its ABI-2280 program and are thrilled to be able to lead this round of financing. The company has advanced the development of ABI-2280 to patients with CIN 2,3 and is now poised to expand clinical development into high-risk HPV infection. ABI-2280 can make the World Health Organization’s screen-and-treat approach to HPV infection a reality,” said Dr. Segal.

Dr. Goodman added, “With MPM-BioImpact’s growing focus on the field of virology, Antiva represents the type of impactful investment that we are looking to make in this space. We look forward to supporting Kristine in her new role as CEO and seeing the continued progress that is made under her leadership.”

Ms. Ball joins Antiva with more than 20 years of executive experience in the life sciences industry across companies of all stages ranging from discovery to clinical to commercial. She has significant transactional expertise, having participated in multiple initial public offerings, corporate M&A deals, partnerships and financings. Ms. Ball most recently served as chief executive officer of Soteria Biotherapeutics, a venture backed immuno-oncology company and previously held leadership positions at Menlo Therapeutics, Relypsa, Inc., and KAI Pharmaceuticals, and served on the board of Forty Seven, Inc., until its acquisition by Gilead.  Ms. Ball currently sits on the board of Atreca, Inc., a publicly traded, clinical-stage oncology company.

“I am deeply grateful for this opportunity to join Antiva at such an exciting time in the company’s maturation. ABI-2280 has tremendous potential to play a significant role in advancing both global health and women’s health, bringing about a long-needed breakthrough in HPV infections and HPV-related cancers in both men and women,” stated Ms. Ball. “I am eager to carry forward the significant momentum that has been generated by the Antiva team and look forward to the important upcoming clinical development milestones that will move us closer to this goal. I am also excited to be able to work closely with Gail in her new role as board chair, leaning on the experience and knowledge she has gained during her time as president and CEO.”   

“I take great pride in turning the CEO role over to Kristine with the company in such a strong position following this transformative financing. She is a talented and experienced life science executive who is perfectly suited to lead Antiva as it expands clinical development of ABI-2280,” said Ms. Maderis. “I look forward to remaining intimately connected to the company in the role of board chair and offer a special thanks to Steve James, who has provided Antiva with great leadership and guidance as board chair and will remain an executive advisor to the company.”

About HPV-Related Diseases and Cervical Cancer

Human Papilloma Virus (HPV) is so common that nearly all sexually active men and women are infected with the virus at some point in their lives. Many of these are transient infections the body is capable of clearing, but this typically takes months to years.  When the infections persist, they are known to drive the formation of malignancies, including cervical, anal, vulvar, penile, and head and neck cancers.

The introduction of prophylactic vaccines for HPV was a major step forward in the fight against HPV-associated cancers by preventing infection by certain high-risk HPV subtypes. However, due to low adoption rates in the US, EU, and Japan, and limited access to the vaccines in developing countries, HPV infections and the disease states driven by such infections remain a major unmet clinical need.

Globally, cervical cancer is the fourth most common cancer in women and as such represents a major public health problem. According to the World Health Organization, an estimated 604,000 women were diagnosed with cervical cancer worldwide and approximately 342,000 women died from the disease in 2020.

About Antiva Biosciences
Antiva Biosciences, Inc. is a clinical-stage biopharmaceutical company developing novel, topical therapeutics for the treatment of diseases caused by HPV infection. The company, based in South San Francisco, was founded in 2012 by Dr. Karl Hostetler of The University of California San Diego. The company’s lead drug candidate, ABI-2280 is being developed as a topical treatment for high-grade cervical intraepithelial neoplasia (HSIL, CIN 2,3) and for women with high-risk HPV infection.

For more information, please visit: www.antivabio.com.

Contact Information:

Kristine Ball
Antiva Biosciences, Inc.
650-822-1400
[email protected]

Tim Brons
Vida Strategic Partners (media)
646-319-8981
[email protected]

SOURCE Antiva Biosciences, Inc.


DeepHow Raises $14M Series A Funding to Transform How Enterprises Capture and Transfer Technical Know-How

Funding round led by Owl Ventures follows DeepHow’s 3x year-over-year growth since launching its enterprise AI-powered knowledge-capture and learning platform

DETROIT, April 27, 2023 — DeepHow, the AI company that turns technical know-how into smart, how-to training videos, has closed $14M in Series A funding. Owl Ventures, a specialist in education technology investing, led the round, with participation from another new investor: LG Technology Ventures. Existing investors Sierra Ventures, Qualcomm Ventures, Osage Venture Partners, and Foothill Ventures also participated in this round.

DeepHow plans to invest in go-to-market initiatives to accelerate its business growth, and to ramp up its investments in product, engineering, and generative AI innovation. In response to customer demand, DeepHow has already fast-tracked development of powerful product enhancements that leverage the power of generative AI to accelerate SOP video creation, multimodal workflow generation, AI chat assistance, and strategic knowledge mapping.

“Today, manufacturers are under intense pressure to improve efficiency and reduce costs while meeting growing customer demands. At the heart of this transformation is Industry 4.0, which leverages advanced technologies such as AI, IoT, and automation to achieve operational excellence,” said Dr. Sam Zheng, CEO and co-founder of DeepHow. “Realizing the full potential of Industry 4.0 requires more than just technology investment, it also requires a strategic approach to capturing, sharing, and transferring knowledge across teams and departments. This oversubscribed Series A round underscores that our investors share our vision. It also demonstrates their confidence in our ability to build on our technical leadership and accelerate our go-to-market operations.”

DeepHow’s compelling value proposition for the manufacturing and service industries is fueled by the confluence of several industry trends that are driving demand for workers who can quickly assimilate technical skills. Among the forces that are shaping industry globally are the rapid evolution of advanced technology in use on the factory floor, the digitalization of manufacturing associated with Industry 4.0, the restructuring of global supply chains, and a paradigm shift in the way people prefer to learn.

“The need to capture the skills and know-how of senior, experienced workers—and then transfer that knowledge through engaging and efficient training during on-boarding and through reskilling initiatives has never been more important,” said Ian Chiu, managing director at Owl Ventures. “Over 70+ global customers, the majority of them multinational enterprise companies, are leveraging DeepHow’s AI-powered training platform to streamline the capture and transfer of technical skills and know-how — compressing project time by 10x, boosting worker performance by 25%, and dramatically reducing overall training and development costs. We’re excited to be partnering with Sam, Patrik, and the entire DeepHow as they continue to scale and expand on their market leadership.”

“At LG Technology Ventures, we are excited to support visionary founders who are leading the Industrial 4.0 era,” said Anshul Agarwal, managing director of LG Tech Ventures. “Ever since we met Sam and Patrik, we were impressed by their obsession with customers and the design-led product that they have built. We look forward to partnering closely with the DeepHow team as they deploy their product to factories around the world.”

“The growing skills gap and consequent loss of productivity in the manufacturing industry will cause a paradigm shift in technical training and I am thrilled to continue to support DeepHow on their mission to become the leading solution in this sector,” said Ben Yu, managing partner at Sierra Ventures.

About LG Technology Ventures

LG Technology Ventures, established in 2018 in Silicon Valley, is the venture capital investment arm of the Korea-based LG Group. Its team consists of experienced investors, entrepreneurs, technologists, and industry domain experts. LG Technology Ventures manages over $480 million of fund assets and invests in early-stage startups in artificial intelligence, mobility, electrification, advanced materials, climate technologies, life-sciences, next generation display, XR, Web3, mobile, and 5G. They create value for LG portfolio companies by helping them develop strategic partnerships with LG Companies. For more information, please visit lgtechventures.com

About Owl Ventures

Owl Ventures is the largest venture capital fund in the world focused on the EdTech market, with over $2 billion in assets under management. The Silicon Valley-based firm invests in the world’s leading education technology companies across the education spectrum, encompassing PreK-12, higher education, future of work (career mobility/professional learning), and “EdTech+” (the intersection of EdTech and other major industries). Owl Ventures has deep domain expertise and leverages a global network of limited partners, investors, and strategic partners to help entrepreneurs scale their businesses into transformative category leading companies. Learn more at OwlVC.com. Owl’s annual Education Outcomes Report can be viewed at OwlVC.com/outcomes.

About DeepHow

DeepHow was founded in 2018 by a team of ex-Siemens researchers and engineers who saw an unmet need to transfer knowledge in the skilled workforce market. They developed an AI-powered, video-centric knowledge-capture and learning platform that bridges the skills gap in the manufacturing, service, and construction industries. DeepHow streamlines the capture and transfer of technical skills and know-how — compressing project time by 10x, boosting worker performance by 25%, and dramatically reducing overall training and development costs. For more information, visit deephow.com.

SOURCE DeepHow Corporation


Join K-Startup Grand Challenge 2023 and Boost Your Business

Apply now and win a total of $270,000 in awards. Participants will also receive diverse benefits and support in line with South Korea’s $8B startup investment plan.

SAN FRANCISCO, April 26, 2023 — Global startups are invited to participate in the 8th K-Startup Grand Challenge (KSGC), an annual accelerator program designed to nurture the next generation of superstar startups.

Scheduled from July 25 to November 10 this year, the equity-free acceleration program allows fledgling startups from around the world to test and run their ideas in South Korea, providing a stepping stone to expand further into Asia.

Finalists of the state-run program will have the chance to attract investments from local venture capitalists, work on proof-of-concept projects with tech giants like Samsung and LG, and build business relations with established companies such as webportal giant Naver and ecommerce heavyweight Coupang.

In line with the government’s startup support policies, investments by big corporates, including Posco, KB Financial Group, Hanwha Group, have been increasing over the past years. Corporates contributed to funding rounds that totaled more than $17.3B in 2022, accounting for 54% of the total investments in the nation, according to the Tech Scaleup South Korea report.

South Korea’s 95% smartphone penetration rate and advanced network infrastructure will also make it easy for ecommerce and mobile startups to operate.

Since its inception in 2016, the KSGC has successfully supported startups from around the world, including Europe, North America, and Southeast Asia.

  • Apostera, an augmented reality (AR) and mixed reality (MR) software firm, was acquired by HARMAN, a Samsung subsidiary.
  • Bear Robotics raised $81M Series B to scale up mobile robots in the hospitality industry.
  • The participating startups raised a total of 68.2B Korean won ($51.3M) in funding while their aggregated sales reached 14.9B Korean won ($11.2M).

Apply now at the KSGC website from  April 10 to May 18 (4:00PM, KST).

Who is eligible to apply?

Startups who have been operating for less than 7 years or have at least one founding team member who is not a Korean national and at least one product or service with measurable traction are eligible. They must have a clearly defined objective of expanding their business into the Asian market, with the Korean market serving as a gateway.

Instructions and registration information are available at:

Website: https://www.k-startupgc.org/
Facebook: https://www.facebook.com/kstartupgc

SOURCE KIC Silicon Valley


LMS365 Raises $20 Million Growth Round to Fuel Expansion

AARHUS, Denmark, April 26, 2023 — Pioneering learning management system LMS365, has raised $20 million in growth capital to fund its continued global expansion.

The investment was led by New York City-based Blue Cloud Ventures with participation from Kamet Capital and existing shareholders. Blue Cloud Ventures is a late-stage SaaS-focused venture capital fund with prior investments in several leading workforce management and learning software companies globally. As part of the funding, Mir Arif and Eric Guardiola of Blue Cloud Ventures will be joining the LMS365 board and Victor Yaw will be joining as a board observer.

LMS365’s user-centric learning management system is the only learning platform built into Microsoft Teams, Microsoft Viva and Microsoft365. With millions of users in 60+ countries, LMS365 enables some of the world’s leading organizations to effectively manage employee learning and training.  Empowering employees with its element of ‘Learn Like You’ – i.e. allowing employees to learn in their familiar flow of work – has been key to LMS365’s success.

“Raising a round of this magnitude in the current climate is outstanding for the whole team and a testament to all the hard work put into getting to this point,” said Rasmus Holst, CEO of LMS365. “This capital injection represents a significant change in gear for our business. The decision by our CTO, Freddy Bang, to build on Teams in 2016 sparked a phenomenal growth journey, and now we are ready for the next chapter.

“We are thrilled to partner with LMS365 and its management team,” said Mir Arif, Managing Partner of Blue Cloud Ventures. “We have tracked the LMS market for a long time and were impressed by the Microsoft Teams-native platform built by LMS365 which provides seamless deployment and ease of use for their customers.

“We are very familiar with the Microsoft and LMS ecosystem and are strong believers in the unique and differentiated position that LMS365 has carved out in this large and growing market,” said Eric Guardiola, Principal at Blue Cloud Ventures.

LMS365 has grown organically through its tight integration with Microsoft, and by tapping into the global business need that COVID-19 highlighted – the ability to onboard, train and develop employees regardless of their location. 

“We see a clear window of opportunity in the market where we can accelerate,” said Henrik Jeberg, Chief Strategy Officer of LMS365. “While we are proud of our growth rates, Microsoft Teams adoption has also grown fast, so we expect to continue to invest in our core market, and we also see Microsoft Viva as a clear opportunity.

LMS365 expects to continue to grow geographically after successfully expanding its market access through the acquisition of distribution partners in the U.S., Germany and Australia. By focusing on adjacencies, LMS365 aims to offer additional functionality to customers and users. “We will use M&A strategically going forward, including in relation to product development,” added Henrik Jeberg.

LMS365 believes learning will only become more strategic for businesses in the future. Businesses expect that employees will take increasing control of their professional development – seeking knowledge in their own time for their personal career journey and to benefit their employer.  Skills will continue to be a strong currency in the future job market.

About LMS365
At LMS365, we’re on a mission to place learning in the hands and hearts of people — empowering them to learn for life. Like no one else. As the only learning platform built into Microsoft 365 & Teams, we help millions of users within global organizations embrace the modern digital workplace and learn in their individual and familiar flow of work. Because we believe in putting people over platform. Today, with offices in Europe, Australia, and the US, we excite and enable users in 60+ countries to grow smarter. To unleash their full potential. To train, work, and learn like you. For more information, please visit www.lms365.com.

About Blue Cloud Ventures

Blue Cloud Ventures (BCV) is a software-focused later stage venture capital firm based in New York City. The fund targets investments in leading business application, infrastructure and open source software companies. Some of BCV’s past and present portfolio companies include Arctic Wolf Networks, Clari, Cloudbees, Druva, Go1, Iterable, NGINX, Templafy, Pax8 and Wrike. For more information on BCV and our portfolio companies, please visit www.bluecloudventures.com.

Contact:
Jamie Hornberger 
585-944-7456 
[email protected] 

SOURCE LMS365


Avaada Group raises US $1 billion funding for manufacturing of Green Hydrogen, Solar PV modules and growth of Renewable Energy platform from Brookfield

This is part of its US$ 1.3 bn fund raise plan

MUMBAI, India, April 26, 2023 — Avaada Group today announced that it has raised US $ 1.07 billion to fund its green hydrogen and green ammonia ventures in India as a part of its ongoing US$ 1.3bn fund raise plan.

Brookfield Renewable, through its Brookfield Global Transition Fund (BGTF) will be investing up to US $ 1 billion in Avaada Ventures Private Limited.

Global Power Synergy Public Company Limited (“GPSC”), will further invest US $ 68 million in Avaada Energy Private Limited for releasing debt obligations and supporting the growth.

The Group is also in advanced discussions with potential investors to raise another US$ 200 million.

Avaada Group has become future-ready in the global Energy Transition theme and has diversified into manufacturing of Green Hydrogen, Green Ammonia. The Group has also expanded its footprint into the Solar PV supply chain with manufacturing of solar cell and module. Avaada currently operates a renewable energy portfolio of ~4 GW with plans to reach 11 GW by 2026.

Vineet Mittal, Chairperson and Founder, Avaada Group commented: “Avaada Group is a leading player in energy transition in India, building an integrated ‘Sand to molecule’ business aligned for the global energy transition towards decarbonization. I am delighted to welcome Brookfield to join us in our next phase of growth. The collaboration will support us in pursuing exciting opportunities as we play a critical role in meeting the exponential growth of sustainable energy and position ourselves at the forefront of the global energy transition. I’m also thankful to GPSC for their continued support in fulfilling our mission of delivering promise of a sustainable future for posterity.”

Nawal Saini, Managing Director, Renewable Power & Transition, Brookfield added, “We are pleased to be investing in Avaada through the Brookfield Global Transition Fund, which focuses on investments that accelerate the progress to a net-zero carbon economy. This strategic partnership will leverage Brookfield’s global track record, access to capital and operational expertise alongside Avaada’s strong local footprint, to enable their vision for the energy transition business. Brookfield remains committed to supporting the next generation of clean energy technologies and contributing to India’s net-zero aspirations.”

Avaada Group:

Social entrepreneur Vineet Mittal-led Avaada Group is an integrated energy platform with business interests ranging from manufacturing solar cells, modules and electrolysers to renewable power generation, green hydrogen, and green ammonia production. Avaada Group’s flagship company Avaada Energy is India’s fastest-growing renewable energy IPP. Within five years, it has developed an impressive portfolio of 4 GW and the firm plans to reach 11 GW by 2026 and 30 GW by 2030.

The solar manufacturing business of Avaada is in the advanced stages of developing a manufacturing facility for wafer, cell, and modules. The group is also executing Green Ammonia projects across multiple geographies.

Logo: https://mma.prnewswire.com/media/2063725/Avaada_Logo.jpg

SOURCE Avaada Group


aiXplain Raises $8M in Seed Funding to Accelerate AI Solutions Development

No-code/low-code platform enables any company to quickly build robust AI applications to compete in the automation economy

SAN JOSE, Calif., April 26, 2023 — aiXplain, the industry’s first no-code/low-code integrated AI development platform, announced today that it has raised $8 million in seed funding led by Transform VC and Calibrate Ventures.

aiXplain is the industry’s first end-to-end integrated platform for quick development and delivery of AI projects. aiXplain’s no-code/low-code integrated development environment (IDE) enables users to develop, manage, benchmark, experiment and one-click deploy AI assets. Initially attracted to the platform’s ease of use and ability to increase speed-to-delivery for AI projects, aiXplain customers create more advanced applications by accessing a large and growing number of AI assets in data, models, pipelines and benchmarks. Through the aiXplain marketplace, users can access aiXplain’s own as well as third-party assets from OpenAI, Google, AWS, Azure and dozens of other AI technology providers.

“Today, the hardest part of delivering business-altering AI is bringing everything together: data preparation, model training, benchmarking, and deployment all involve different skill sets, diverse tools, and multiple groups,” said Hassan Sawaf, CEO and founder of aiXplain. “This complexity creates a tremendous barrier to success. In short, AI projects are difficult and costly to set up and deliver. We have built aiXplain to address this huge problem.”

Gartner states that 85% of AI projects fail due to unclear objectives and obscure R&D project management processes. As well, 87% of R&D projects never get to the production phase, while 70% of clients indicate minimal or even no impact from AI. “These numbers speak to the tremendous size of the problem in designing, building and iterating on meaningful AI projects”, said Raed A. Masri, founding partner of Transform VC.

“In every industry, the race is on to deploy AI to improve competitiveness, yet many companies don’t have the technical teams and resources needed to develop, test, and deploy cutting-edge AI solutions. With aiXplain, even non-technical users can quickly create robust AI applications,” said Jason Schoettler, managing partner at Calibrate Ventures. “Hassan, with over 25 years of experience building AI models at companies such as Amazon, Facebook, and eBay, has assembled an exceptional team of technologists and business strategists who clearly see the democratized future of AI.”

In under a year, aiXplain has scaled rapidly among high-growth technology companies and Fortune 500 enterprises alike. Marco Trombetti, founder and CEO at Translated, a world leader in machine translation with over 200,000 customers worldwide, credits aiXplain with automating and streamlining its data-sourcing and machine learning development processes, resulting in new world-class products and generating fresh revenue. “Thanks to our deep partnership with aiXplain, we continue to expand our leadership position in the field of advanced natural language processing,” said Trombetti. “aiXplain’s enterprise-strength platform enables us to power faster and more profitable global expansions for companies such as Airbnb and Uber.”

Bruce Lucas, founder and CEO of Slide, one of the largest insur-techs in the US, credits aiXplain with rapidly producing AI and machine learning solutions that leverage Slide’s proprietary big dataset in revolutionary ways. “Using the aiXplain toolkit, our team was able to rapidly develop a prototype of a multimodal agent, analogous to Microsoft’s CoPilot or OpenAI’s ChatGPT,” said Lucas. “This new agent will support our examiners in the complex process of claims handling.”

Experience aiXplain:

  • Sign up for a demo or kick off a free project to test out our platform at aixplain.com and experience what it’s like to effortlessly gain control of your AI design, development and benchmarking.
  • aiXplain is hiring – explore open opportunities at https://www.aixplain.com/careers

About aiXplain

aiXplain is the industry’s first end-to-end integrated platform for quick development and delivery of AI projects and solutions. aiXplain’s no-code/low-code integrated development environment (IDE) enables users to develop, manage, benchmark, experiment and deploy AI assets quickly and efficiently. aiXplain users come for productivity and stay to benefit from an ever-growing network of AI assets including data, models, pipelines, and benchmarks. Customers can design their own AI pipeline, benchmark their model against other models, use their own datasets or benefit from available datasets—all to easily create and maintain AI systems.

Contact:  [email protected]

About Calibrate VC

Calibrate Ventures is an early-stage venture capital firm investing in deep tech that can be applied at scale. Calibrate uses its expertise in AI, computer vision, and robotics to invest in technologies that can be integrated into broad, near-term industry applications in food, health, logistics, manufacturing, and security, among others. Calibrate typically leads Seed and Series A rounds, backing technical founders who have demonstrated disruptive vision in their fields. Founded in 2017, Calibrate is based in Pasadena, California, and invests throughout the United States.

About Transform VC

San Francisco-based Transform VC identifies and funds untapped and underrepresented technology founders for transformative impact & exceptional returns.  With a goal to enable 1000 tech founders to positively impact one billion lives and an affinity for immigrant, female, and BIPOC founders, Transform VC focuses on AI and technologies solving climate and social challenges.

SOURCE aiXplain, inc.